Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Sofosbuvir: First Global Approval
2014
Identification of interferon-stimulated genes that attenuate Ebola virus infection
2020 StandoutNobel
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Cancer statistics, 2018
2018 Standout
Cancer Statistics, 2021
2021 Standout
Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
2012
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus
2011
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Hepatocellular carcinoma
2018 Standout
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
2011
Hepatitis C virus—host interactions, replication, and viral assembly
2012
Treatment triumphs
2014 StandoutNatureNobel
Serum Cholesterol and Statin Use Predict Virological Response to Peginterferon and Ribavirin Therapy†,‡
2010
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
2013 StandoutNobel
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
2017
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Shared and Distinct Functions of Type I and Type III Interferons
2019
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
2010
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
2012
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C
2012
A functional genomic screen reveals novel host genes that mediate interferon-alpha’s effects against hepatitis C virus
2011
The role of resistance in HCV treatment
2012
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication
2012
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
2011
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Metazoan MicroRNAs
2018 Standout
Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations
2015
Antiviral strategies in hepatitis C virus infection
2012
Drug discovery for a new generation of covalent drugs
2012
Successes and Challenges on the Road to Cure Hepatitis C
2015
IL28B single nucleotide polymorphisms in the treatment of hepatitis C
2011
Update on hepatitis C virus resistance to direct-acting antiviral agents
2014
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
2011
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
2011
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Global control of hepatitis C: where challenge meets opportunity
2013
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
2013
Hepatitis C Virus: 30 Years after Its Discovery
2019 StandoutNobel
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
2014
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
HCV and the hepatic lipid pathway as a potential treatment target
2011
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
2020 Standout
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
2015
Treatment of Hepatitis C
2014
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Protease inhibitor therapy for hepatitis C virus-infection
2018
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
2013
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
2014
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS 5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
2014
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
2018 StandoutNobel
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
2014
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
The resurgence of covalent drugs
2011
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
A Heck–Matsuda Process for the Synthesis of β‐Arylethenesulfonyl Fluorides: Selectively Addressable Bis‐electrophiles for SuFEx Click Chemistry
2016 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
2017 StandoutNobel
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
2015
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
2012
Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
2011
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Works of Mitchell Davis being referenced
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection
2015
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
2009
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
2013
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
2010
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
2016
1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY
2013
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection
2015
LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
2015
1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
2012
2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)
2010